The first Phase III study of an alpha-pharmaceutical (Radium-223 Chloride -- Alpharadin) in patients with bone metastases from advanced prostate cancer has shown that it can prolong survival significantly. Until now, options for these patients have been very limited. The ALSYMPCA trial had to be stopped early after interim analysis revealed that patients receiving the best standard treatment ...